Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IGBA Makes Access Pact With WHO

Promotes The Use Of Generics And Biosimilars

Executive Summary

The World Health Organization has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the International Generic and Biosimilar Medicines Association to promote access to medicines.

You may also be interested in...

WHO Committee Wants Biosimilars Added To Pre-Qualification

As biosimilars are added to the WHO’s list of essential drugs, an expert committee wants the global body to expand its pre-qualification program to cover more biosimilars.

IGBA Favors WHO System Over Originator Database

In the final of three exclusive interviews, IGBA chair Jim Keon and secretary general Suzette Kox provide the latest update on global issues affecting the off-patent industries, including originator intellectual-property tactics in the form of the WIPO’s and IFPMA’s Pat-INFORMED database.

WIPO Patent Database Is Flawed And Promotes Linkage

An online register of global patent information for medicines launched by the WIPO and brand industry body IFPMA serves as a tool for patent linkage, contains no mechanisms to ensure accuracy, and is inappropriate for a UN agency to endorse, according to the IGBA.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts